Health Care · Biological Products, (No Diagnostic Substances)

GILD Gilead Sciences SEC Filings & Insider Trading Activity 2026

company
CIK 882095153 filings
Nasdaq 100
S&P 500

GILD at a glance

Gilead Sciences (GILD, SEC CIK 882095) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Gilead Sciences (GILD) reported revenue of $29.4 billion (up 2.4% from FY2024) and net income of $8.5 billion. Diluted EPS was $6.78.
  • As of September 30, 2026, 51 institutional investment managers tracked by SignalX reported holding Gilead Sciences (GILD) shares worth $78.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Mercier Johanna on November 16, 2026 of 13,922 shares at $169.97 per share.
  • Gilead Sciences reported 5 positions worth $1.5 billion in its 13F-HR for Q3 2026, filed November 6, 2026. Its largest holdings were Arcus Biosciences Inc. (RCUS) at 55.5%, Lakefront Biotherapeutics (LKFT) at 34.2% and Assembly Biosciences Inc. (ASMB) at 8.0%.
  • In the last 90 days, GILD insiders reported 0 open-market purchases ($0) and 32 open-market sales ($41.6M) on Form 4, a net sale of $41.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$29.4B
+2.4% vs prior year
Insiders · 90 days
0 buys · 32 sells
Net −$41.6M
13F holders
51 funds
$78.6B · −2 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • IRA + MFN pricing: Biktarvy selected for Medicare price negotiation effective 2028; Gilead signed Dec 2025 agreement implementing MFN Medicaid prices and pausing Section 232 tariffs for 3 years
  • Pharmaceutical tariff exposure: U.S. administration announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; Gilead sources significant raw materials and intermediates from outside U.S.
  • CAR T-cell supply chain: relies on third-party apheresis centers, shippers, and single-source tocilizumab/corticosteroid suppliers; disruption risks product loss and regulatory action
  • BIOSECURE Act operational risk: prohibits U.S. agency contracts with certain foreign biotech entities used by Gilead in clinical trials and commercial manufacturing, threatening supply and trial timelines
  • Revenue concentration: ~90% of U.S. gross product sales flow through just three wholesalers; Cardinal Health, Cencora, and McKesson

Management Discussion & Analysis

  • Revenue $29.4B in 2025, up 2% YoY; HIV +6% to $20.8B best performer; Veklury -49% to $911M worst performer
  • Product gross margin 78.4% vs 78.2% (+29 bps); SG&A down 5% to $5.8B; effective tax rate 13.1% vs 30.5%
  • Net income $8.5B vs $480M YoY; driven by absence of $3.8B CymaBay IPR&D charge and lower IPR&D impairments ($590M vs $4.2B)
  • Operating cash flow $10.0B; dividends $4.0B; buybacks $1.9B; debt repaid $1.8B; cash/securities $10.6B at year-end
  • 2026 outlook: HIV growth expected; offset by Veklury decline, Cell Therapy competitive headwinds, and U.S. policy-related impacts

Business Overview

  • Biopharmaceutical company focused on HIV, viral hepatitis, COVID-19, and oncology; commercial portfolio of 25+ therapies distributed across 35+ countries via wholesale channel (~90% of U.S. sales through 3 wholesalers)
  • Yeztugo/Yeytuo (lenacapavir) approved as first and only twice-yearly HIV PrEP option in both U.S. and EU; multiple BLA filings pending for anitocabtagene autoleucel (multiple myeloma) and expanded Trodelvy indications in TNBC first-line and NSCLC
  • Pipeline expansion into immuno-oncology via Arcus collaboration: domvanalimab + zimberelimab (anti-TIGIT + anti-PD-1) in Phase 3 for first-line metastatic NSCLC; new competitive thrust beyond CAR-T and ADC
  • ~17,000 employees as of December 31, 2025
  • Biktarvy patent litigation settled with Lupin, Cipla, and Laurus in October 2025; no generic entry expected before April 1, 2036 in the U.S.

AI summary of the GILD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Third-quarter revenue $8.3B, up 7% YoY from $7.769B
  • Product gross margin 81.0% vs 78.6% YoY
  • Best segment HIV: $6.2B, up 18%; worst Veklury: $86M, down 69%
  • Operating cash flow $11.152B versus $6.692B; cash and equivalents $6.4B
  • Near-term headwinds: competitive Cell Therapy demand, lower COVID hospitalizations, $1.75B Trodelvy IPR&D impairment

Risk Factors

  • New pricing risk: Biktarvy selected for Medicare Maximum Fair Price, effective January 2028, with CMS completing price-setting in October 2026
  • Regulatory risk: 100% tariffs on patented pharmaceuticals began taking effect in July 2026, subject to exemptions and potential modifications
  • Clinical-development risk: Phase 3 EVOKE-03 discontinued in June 2026, triggering an impairment charge
  • Operational risk: CAR T-cell manufacturing delays or quality issues could constrain Yescarta and Tecartus supply
  • Financial risk: $32 billion U.S. investment through 2030 could increase capital expenditures, operating expenses and cash-flow variability

AI summary of the GILD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 product sales $8.3B, up 13%; excluding Veklury, sales rose 16% to $8.2B, showing strong underlying growth
  • HIV sales increased 18% to $6.2B, led by Biktarvy sales up 10% to $4.1B

Item 2.02: Results of Operations and Financial Condition

  • Gilead announced third-quarter 2026 results for the period ended September 30, 2026
  • Full financial results and GAAP-to-non-GAAP reconciliations available in Exhibit 99.1
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue rose 10% to $7.8B, led by HIV sales up 12% to $5.7B and Trodelvy sales up 26% to $457M
  • Biktarvy grew 7% to $3.8B and Descovy surged 48% to $967M, reinforcing HIV portfolio momentum

Item 2.02: Results of Operations and Financial Condition

  • Gilead announced second-quarter 2026 results for the quarter ended June 30, 2026
  • Full financial results and operating metrics are in Exhibit 99.1
Filed May 20, 2026Full analysis →

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 signals a new direct financial obligation or off-balance-sheet arrangement

Item 8.01: Other Events

  • Gilead entered an underwriting agreement on May 14, 2026, for issuance and sale of debt notes
  • Barclays, BofA Securities and Citigroup acted as underwriter representatives

Item 1.01: Entry into a Material Definitive Agreement

  • $3.0B senior-note issuance across 2028, 2029, 2031 and 2034 maturities
  • Fixed semiannual coupons ranging from 4.250% to 4.900%

AI summaries of GILD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GILD

Don't miss the next GILD filing

  • Alerts as it files. A push when GILD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GILD, by share count.
  • Ask anything. An AI agent that reads every GILD filing and answers with sources.

GILD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Mercier JohannaMNov 16, 2026$72.34
Mercier JohannaSellNov 16, 2026$169.97
Mercier JohannaMNov 16, 2026-
Dickinson Andrew DSellNov 16, 2026$171.47
Mercier JohannaSellNov 16, 2026$171.09
Mercier JohannaSellNov 16, 2026$171.69
Kramer Kelly A.MNov 12, 2026$66.92
Kramer Kelly A.SellNov 12, 2026$168.23

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$28.8B$29.4B
Operating Income-$1.7B$10.0B
Net Income$5.7B$480.0M$8.5B
Op. Margin-5.8%34.0%
Net Margin-1.7%28.9%
Balance Sheet
Total Assets-$59.0B$59.0B
Equity$22.8B$19.3B$22.7B
ROE24.8%2.5%37.5%
Per Share
EPS$4.50$0.38$6.78
Cash Flow
Operating CF-$10.8B$10.0B
CapEx$585.0M$523.0M$563.0M

Source: XBRL data in Gilead Sciences (GILD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GILD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GILD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202651$78.61B
Q2 202653$74.30B
Q1 202656$83.07B
Q4 202552$73.29B
Q3 202552$63.61B
Q2 202550$60.27B
Q1 202549$42.86B
Q4 202448$28.41B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 411 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

Gilead Sciences top 13F holdings, Q3 2026

Largest reported positions by market value, from the 13F-HR filed Nov 6, 2026

Gilead Sciences 13F holdings for Q3 2026
#CompanyWeightValueSharesvs Q2 2026
1Arcus Biosciences Inc.RCUS55.45%$811.7M31,424,760Held
2Lakefront BiotherapeuticsLKFT34.24%$501.3M16,707,477Held
3Assembly Biosciences Inc.ASMB7.99%$116.9M4,977,089Held
4Kyverna Therapeutics Inc.KYTX1.92%$28.1M4,126,119Held
5Xilio Therapeutics Inc.0.40%$5.9M650,389Held

Source: Gilead Sciences 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work

GILD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 16, 2026--
4Nov 9, 2026--
13F-HRNov 6, 2026-
4Nov 6, 2026--
4Nov 2, 2026--
10-QOct 30, 2026Analysis
8-KOct 29, 2026Analysis-
4Oct 16, 2026--
4Oct 16, 2026--
4Oct 2, 2026--
4Sep 23, 2026--
4Sep 16, 2026--
4Sep 16, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 2, 2026--
4Aug 27, 2026--
4Aug 21, 2026--
4Aug 18, 2026--
4Aug 18, 2026--

Related Health Care companies

All Health Care →

GILD SEC filings: frequently asked questions

Are GILD insiders buying or selling?

In the last 90 days, Gilead Sciences (GILD) officers, directors and 10% owners reported no open-market purchases and 32 open-market sales worth $41.6 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GILD stock?

As of September 30, 2026, the largest Gilead Sciences (GILD) holders among the 13F filers tracked by SignalX were BlackRock ($18.7 billion), Vanguard Capital Management LLC ($12.1 billion), State Street Corp ($9.1 billion), Invesco Ltd ($5.8 billion), Vanguard Portfolio Management LLC ($5.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was GILD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Gilead Sciences (GILD) reported revenue of $29.4 billion (up 2.4% from FY2024) and net income of $8.5 billion. Diluted EPS was $6.78. The figures come from the XBRL data in the 10-K.

What are the main risks in GILD's latest 10-K?

In the 10-K filed February 24, 2026, Gilead Sciences (GILD) flagged: IRA + MFN pricing: Biktarvy selected for Medicare price negotiation effective 2028; Gilead signed Dec 2025 agreement implementing MFN Medicaid prices and pausing Section 232 tariffs for 3 years. Pharmaceutical tariff exposure: U.S. administration announced plans for up to 100% tariffs on imported branded/patented pharmaceuticals; Gilead sources significant raw materials and intermediates from outside U.S. (AI summary of the Risk Factors section.)

What did GILD report in its latest 8-K?

Gilead Sciences (GILD) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 product sales $8.3B, up 13%; excluding Veklury, sales rose 16% to $8.2B, showing strong underlying growth.

What stocks does Gilead Sciences own?

In its 13F-HR for Q3 2026 (filed November 6, 2026), Gilead Sciences reported 5 positions worth $1.5 billion. The largest were Arcus Biosciences Inc. (RCUS), 55.5%; Lakefront Biotherapeutics (LKFT), 34.2%; Assembly Biosciences Inc. (ASMB), 8.0%; Kyverna Therapeutics Inc. (KYTX), 1.9%; Xilio Therapeutics Inc., 0.4%. The top 10 positions were 100.0% of the portfolio.

When does Gilead Sciences file 13F reports?

Gilead Sciences's latest 13F-HR was filed November 6, 2026 and covers the quarter ended September 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q4 2026 report is due by February 14, 2027.

What are the latest GILD SEC filings?

Gilead Sciences (GILD) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 17, 2026.

What is GILD's SEC CIK number?

Gilead Sciences (GILD)'s SEC Central Index Key (CIK) is 882095. EDGAR lists every GILD filing under that number.

Ask anything about GILD

The research agent reads GILD's filings, financials, insider trades and 13F holders, then answers with sources.